Forge Biologics Revenue and Competitors
Estimated Revenue & Valuation
- Forge Biologics's estimated annual revenue is currently $84.2M per year.
- Forge Biologics's estimated revenue per employee is $217,000
- Forge Biologics's total funding is $240M.
- Forge Biologics has 388 Employees.
- Forge Biologics grew their employee count by 45% last year.
Forge Biologics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Forge Biologics?
Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality. We partner with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. We bring expertise in gene therapy manufacturing and therapeutics development to the table, helping champion teams that are navigating the long road from the lab bench to the bedside. With a patients-first approach, we are forging new models for working together to better accelerate these transformative medicines to reach those who need them most.keywords:N/A
Number of Employees
Employee Growth %
Forge Biologics News
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge's mission is to...
Forge Biologics, a Columbus, Ohio-based gene therapy-focused contract development and manufacturing organization, closed a $120m Series B financing. The round was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company ...
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Ci ...
COLUMBUS, Ohio, Jan. 4, 2021 /PRNewswire/ -- Forge Biologics Inc., a gene therapy manufacturing and development company, today announced that the company has received FDA clearance of the Investigational New Drug (IND) to initiate a Phase 1/2 clinical trial evaluating its novel, first-in-human ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|